RxDoctor Payments Data

Gawain Dyer, MD

Ophthalmology · San Antonio, TXNPI 1427286137

Payments from drug & device makers

$86,438in general payments, 2019–2025

Across 186 payments — averaging $464.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$33K
  • Roche TCRC, Inc.$23K
  • ANI Pharmaceuticals, Inc.$11K
  • Alimera Sciences, Inc.$10K
  • AbbVie$4K
  • Eyepoint US, Inc.$2K
  • plus $5K from 16 others
$1,472in research payments, 2019–2025

Across 8 payments — averaging $184.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K
  • Alimera Sciences, Inc.$101

What the payments were for

  • Consulting fees$5003%
  • Speaking & faculty fees$8,50048%
  • Travel & lodging$1,68610%
  • Food & beverage$6,93739%
  • Education$931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,438 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$564,008
Medicare patients
255
Services billed
3,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept375$873,075
VabysmoFaricimab-Svoa72$185,843
Eylea HdAflibercept42$126,000
LucentisRanibizumab18$35,100
OzurdexDexamethasone18$27,460
Prednisolone Acetate131$5,301
LumiganBimatoprost11$4,920
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$2,965
Difluprednate13$1,517
ErythromycinErythromycin Base98$1,164
Timolol Maleate71$1,138
Brimonidine Tartrate42$1,110
MoxifloxacinMoxifloxacin Hcl27$1,088
Latanoprost104$1,064
Dorzolamide Hcl41$925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$524$999,075417 claims
Genentech USA, Inc.Vabysmo$628$185,84372 claims
Genentech, Inc.Lucentis$125$35,10018 claims
AbbVieOzurdex, Lumigan$3,721$32,38029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →